

## Special Issue

# The Use of Targeted Cytokine for Novel Cancer Therapeutics

### Message from the Guest Editors

This Special Issue will address the evolving role of immune modulatory cytokines from their initial use as monotherapeutic recombinant proteins to their more contemporaneous use, for example as modifiers for adoptive T cell immunotherapy. Sustained delivery platforms, such as viral therapy and self-replicating mRNA strategies delivered into the tumor microenvironment, may provide more reasonable clinical delivery schedules while minimizing systemic toxicities. The discovery of new cytokines that are at the convergence of both immune modulation and tumorigenesis will likely serve as the next generation of cytokine therapeutics. Approaches aimed to target cytokine inducible genes and their protein products will be also discussed.

---

### Guest Editors

Prof. Dr. Leonidas C Plataniias

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA

Prof. Dr. Amy Heimberger

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA

---

### Deadline for manuscript submissions

closed (31 August 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/158942](https://mdpi.com/si/158942)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)